摘要:
The present disclosure discloses the chemical synthesis method of the Plesiomonas shigelloides serotype O51 O-antigen oligosaccharide, belonging to the field of chemistry. Source-abundant D-glucose, L-fucose, D-glucosamine and the like are used as raw materials to prepare three glycosylation building blocks, the synthetic route composed of 11 reaction modules is designed, and through the optimization of protecting group and the optimization of the time of introducing functional group, the preparation of the target oligosaccharide chain is successfully achieved. The oligosaccharide chain prepared in the present disclosure has the advantages of cheap and easy-to-get raw materials, and simple and easy-to-repeat preparation method. The present disclosure will have good application prospects in the aspects of development of new drugs and vaccines of Plesiomonas shigelloides, and the like.
摘要:
The present invention relates to a phytospingosine derivative generated by a condensation reaction of phytospingosine and maltose or lactose, which is an aldose-based disaccharide, and to a composition containing the same. The phytospingosine derivative of the present invention has high solubility in water compared with phytospingosine, is easy to formulate since the stabilization problem in a solution is solved, and maintains or further enhances the antibacterial effect of phytospingosine.
摘要:
A crystalline LNnT polymorph IV, characterized in that it displays X-ray powder diffraction reflections, based on a measurement using CuKα radiation, at 8.16, 15.41, 39.14, 23.77, 7.77 and 31.15 2Θ angles, and a crystalline LNnT polymorph V, characterized in that it displays X-ray powder diffraction reflections, based on a measurement using CuKα radiation, at 9.15, 10.26, 19.68, 26.06, 20.61 and 1 1.89 2Θ angles, are provided.
摘要:
Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
摘要:
A sialic acid derivative of the formula (I), where the symbols are as defined in the description, is suitable for linking with a cargo for regulating metabolic processes, immune reactions, immunizations or desensitizations of the target organism.
摘要:
The present invention relates to a novel method for synthesising, without a solvent, N-alkyl-glycosyl(di)amine derivatives represented by the following general formula (I): The invention also concerns the use of N-alkyl-glycosyl(di)amine derivatives represented by the general formula (I), and N-alkyl-glycosyl(di)ammonium quaternary salts represented by the general formula (II) and N-alkyl-glycamine derivatives represented by the general formula (III) obtained from N-alkyl-glycosyl(di)amine derivatives represented by the general formula (I), as antibacterial and/or antifungal agents against phytopathogens.
摘要:
Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
摘要:
A process for the simultaneous substitution and crosslinking of a polysaccharide via its hydroxyl functional groups, in an aqueous phase, which includes the following steps: a polysaccharide is placed in an aqueous medium, it is brought into the presence of at least one precursor of a substituent, it is brought into the presence of a crosslinking agent, the substituted and crosslinked polysaccharide is obtained and isolated, wherein process is carried out in the presence of a basic or acidic catalyst, the concentration of which is between 3.16×10−7 and 0.32 mol/L, and at a temperature of less than 60° C. In one embodiment, the polysaccharide is in the form of a gel or hydrogel which is used in particular as augmentation biomaterial.
摘要:
The present invention provides synthetic Pseudomonas aeruginosa lipooligosaccharide (LOS)-based oligosaccharides and conjugates containing various P. aeruginosa serotype-specific oligosaccharide antigens or various core P. aeruginosa oligosaccharide structures or motifs. The invention further provides P. aeruginosa LOS-based immunogenic and immunoprotective compositions and antibodies derived therefrom for diagnosing, treating, and preventing infections caused by P. aeruginosa.